Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Our latest clients all have the potential to grow significantly in the near and long-term future

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Jul 12, 2017 11:13 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 443
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jul 18, 2017 3:13 am

LXRP Presentation and Fact Sheet Now Available

16-page $LXRP Presentation Is Now Available Online:
http://www.networknewswire.info/lxrp/presentation

$LXRP Fact Sheet Is Now Available Online:
http://www.networknewswire.info/lxrp/factsheet
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 443
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jul 18, 2017 3:41 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Well-positioned For Expanding Canadian Cannabinoid Market

Lexaria Bioscience Corp. well-positioned for growth in expanding Canadian cannabinoid market
Canadian market for cannabis extracts and oils expected to top C$1.6 billion by 2020
Company’s patented technology infuses organically sourced hemp oil into molecules of other substances such as lipids, the basis of the human endocannabinoid system
Patented technology enables better-tasting hemp oil-infused gourmet food products with improved bioavailability of cannabinoids
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth in the emerging Canadian cannabinoid market. Lexaria is an innovative revenue-generating company developing and out-licensing proprietary technology for delivering bioactive compounds including cannabinoids.

With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in Canada and elsewhere work to research and develop healthy cannabinoid products. Investment capital in these “plant-to-bloodstream” companies is expected to grow exponentially. As a first mover into this space, Lexaria is well-positioned for increasing market share and revenue.

While cannabinoids such as cannabidiol (CBD) and THC boast a wide range of health benefits, they are poorly absorbed by the human gastrointestinal tract. Lexaria’s products take advantage of the company’s patented technology to offer health-conscious consumers improved absorption and taste of orally-ingested products. Lexaria’s lipophilic enhancement technology is proven to enhance the bioavailability of orally-ingested cannabinoids, thus allowing for lower dosages.

The company is in discussions for or has already signed B2B agreements with companies in Canada, the largest-market states in the U.S., and internationally. Lexaria has also developed its own brands using its patented technology to infuse hemp oil ingredients within lipids in foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

Lexaria continues research and development, signing a collaborative research agreement with the National Research Council of Canada (NRC) in February 2017 to investigate new opportunities in bioavailability enhancement of lipophilic active ingredient compositions. The company believes its patented technology can be utilized for the delivery of nicotine, vitamins, analgesics and a variety of other substances.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 443
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jul 18, 2017 3:44 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Awarded Australian Patent Protecting Cannabis Infused Edibles

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that the Australian Patent Office has granted patent #2015274698, which protects Lexaria’s method of improving absorption, speed of onset and taste of cannabinoid active agents in edible products. The term of the patent is 20 years from June 10, 2015. “We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles utilizing our technology in Australia,” Chris Bunka, CEO of Lexaria, stated in the news release. “This patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will seek additional licensing and product distribution partnering opportunities.” This morning’s announcement follows the award of a similar patent in the United States in October 2016. Lexaria intends to continue developing and solidifying its patent portfolio through the balance of 2017 and 2018.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 443
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Jul 21, 2017 3:23 am

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Commences Lab Work with National Research Council of Canada*

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced the start of laboratory work under its collaborative research project with the National Research Council of Canada (“NRC”). “We are delighted to have commenced formulation development and characterization work together with the NRC,” John Docherty, president of Lexaria Bioscience, stated in the news release. “The NRC team has extensive knowledge and experience in the field of lipid based delivery systems relating to pharmaceutical products, natural health products and functional foods. This collaboration will significantly assist Lexaria in further developing and characterizing its IP portfolio.” Moving forward, several studies will be initiated in an effort to optimize Lexaria’s patented technology enabling delivery of lipophilic active agents within foods, beverages, capsules and other ingestible formats. Per this morning’s update, practical applications of this work could include further broadening or strengthening of Lexaria’s intellectual property portfolio and may also provide the foundation for new commercial arrangements.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 443
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jul 25, 2017 5:34 pm

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Patented Cannabinoid Delivery System Approved

- Patented lipophilic delivery system increases bio-absorption
- Patents cover broad range of lipophilic bio-actives, including cannabinoids, vitamins, other pharma
- 19 patents filed across 44 countries
- First international patent issued and approved in Australia

Any argument over the efficacy of medicinal marijuana is settled science. Recent prestigious clinical studies have provided conclusive evidence that medical cannabinoids are effective medicine for a variety of diseases and ailments (http://nnw.fm/7HnBi). However, the human gastrointestinal tract just doesn’t absorb cannabinoids effectively, and much of what is ingested is simply excreted by the body. Subsequently, onset times and effectiveness vary wildly.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has patented and licenses a novel delivery system which infuses organically sourced hemp oil into the molecules of other substances. The system utilizes lipids, which form the basis of the human endocannabinoid system, increasing both absorption and bioavailability of payload molecules. Lexaria’s lipophilic enhancement technology increases the bio-absorption of cannabinoid edibles by five to 10 times, to roughly equal that of inhalation. The onset times for effectiveness are also reduced by about 75 percent due to rapid bio-absorption by bypassing first-pass liver metabolism. Not only does Lexaria’s methodology dramatically increase effectiveness; it also masks the taste of cannabinoids and eliminates the need for sugar additives.

Lexaria currently has 19 patent applications filed in the U.S. and internationally covering 44 countries. The patents encompass a broad range of lipophilic bio-actives including NSAIDs and Nicotine, as well as food/carrier that can be formulated and delivered using Lexaria’s technology. With U.S. patents already issued, the company announced just last week that its first international patent was accepted and issued in Australia (http://nnw.fm/4h0oA). This development opens the door for Lexaria to bring the Australian cannabinoid edibles market under its umbrella.

Chris Bunka, CEO of Lexaria, stated in the news release. “We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles utilizing our technology in Australia…(the) patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will seek additional licensing and product distribution partnering opportunities.”

Lexaria employs a low-cost, high-margin license and royalty model of revenue generation. By out-licensing to third party partners, the company keeps five to 10 percent of each partner’s gross sales. With multiple royalty agreements already in the works, the company will continue to expand its licensing network as it receives patent approvals. Interestingly, Lexaria’s novel technology has implications across a wide swath of consumer and pharmaceutical delivery protocols. The global impact of Lexaria’s patents and business model will easily reverberate to the bottom line and has only just begun.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 443
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ


Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 1 guest

cron